{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T22:43:18Z","timestamp":1794609798447,"version":"4.9.1"},"reference-count":61,"publisher":"American Society of Hematology","issue":"3","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2006,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The antiviral thymidine analog azidothymidine (AZT) is used to treat several virus-associated human cancers. However, to date the mechanism of AZT action remains unclear and thus, reasons for treatment failure are unknown. Adult T-cell leukemia\/lymphoma (ATL) is an aggressive malignancy of poor prognosis. Here, we report that enduring AZT treatment of T-cell leukemia virus I\u2013infected cells, in vitro and in vivo in ATL patients, results in inhibition of telomerase activity, progressive telomere shortening, and increased p14ARF expression. In turn, this elicits stabilization and reactivation of the tumor suppressor p53-dependent transcription, increased expression of the cyclin-dependent kinase inhibitor p21Waf1, and accumulation of p27kip1, thereby inducing cellular senescence and tumor cell death. While ATL patients carrying a wild-type p53 enter remission following treatment with AZT, those with a mutated p53 did not respond, and patients' disease relapse was associated with the selection of a tumor clone carrying mutated inactive p53.<\/jats:p>","DOI":"10.1182\/blood-2006-01-0067","type":"journal-article","created":{"date-parts":[[2006,3,29]],"date-time":"2006-03-29T04:38:48Z","timestamp":1143607128000},"page":"1021-1029","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":116,"title":["Persistent inhibition of telomerase reprograms adult T-cell leukemia to p53-dependent senescence"],"prefix":"10.1182","volume":"108","author":[{"given":"Abhik","family":"Datta","sequence":"first","affiliation":[{"name":"From the University of Kansas Medical Center, Department of Microbiology, Immunology, and Molecular Genetics, Kansas City, KS; the American University of Beirut, Department of Internal Medicine, Beirut, Lebanon; Hopital Necker Universite Paris V, Centre National de la Recherche Scientifique Unite Mixte de Recherche 8603, Paris, France; and the National Cancer Institute, National Institutes of Health, Metabolism Branch, Center for Cancer Research, Bethesda, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcia","family":"Bellon","sequence":"additional","affiliation":[{"name":"From the University of Kansas Medical Center, Department of Microbiology, Immunology, and Molecular Genetics, Kansas City, KS; the American University of Beirut, Department of Internal Medicine, Beirut, Lebanon; Hopital Necker Universite Paris V, Centre National de la Recherche Scientifique Unite Mixte de Recherche 8603, Paris, France; and the National Cancer Institute, National Institutes of Health, Metabolism Branch, Center for Cancer Research, Bethesda, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uma","family":"Sinha-Datta","sequence":"additional","affiliation":[{"name":"From the University of Kansas Medical Center, Department of Microbiology, Immunology, and Molecular Genetics, Kansas City, KS; the American University of Beirut, Department of Internal Medicine, Beirut, Lebanon; Hopital Necker Universite Paris V, Centre National de la Recherche Scientifique Unite Mixte de Recherche 8603, Paris, France; and the National Cancer Institute, National Institutes of Health, Metabolism Branch, Center for Cancer Research, Bethesda, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Bazarbachi","sequence":"additional","affiliation":[{"name":"From the University of Kansas Medical Center, Department of Microbiology, Immunology, and Molecular Genetics, Kansas City, KS; the American University of Beirut, Department of Internal Medicine, Beirut, Lebanon; Hopital Necker Universite Paris V, Centre National de la Recherche Scientifique Unite Mixte de Recherche 8603, Paris, France; and the National Cancer Institute, National Institutes of Health, Metabolism Branch, Center for Cancer Research, Bethesda, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Lepelletier","sequence":"additional","affiliation":[{"name":"From the University of Kansas Medical Center, Department of Microbiology, Immunology, and Molecular Genetics, Kansas City, KS; the American University of Beirut, Department of Internal Medicine, Beirut, Lebanon; Hopital Necker Universite Paris V, Centre National de la Recherche Scientifique Unite Mixte de Recherche 8603, Paris, France; and the National Cancer Institute, National Institutes of Health, Metabolism Branch, Center for Cancer Research, Bethesda, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Canioni","sequence":"additional","affiliation":[{"name":"From the University of Kansas Medical Center, Department of Microbiology, Immunology, and Molecular Genetics, Kansas City, KS; the American University of Beirut, Department of Internal Medicine, Beirut, Lebanon; Hopital Necker Universite Paris V, Centre National de la Recherche Scientifique Unite Mixte de Recherche 8603, Paris, France; and the National Cancer Institute, National Institutes of Health, Metabolism Branch, Center for Cancer Research, Bethesda, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas A.","family":"Waldmann","sequence":"additional","affiliation":[{"name":"From the University of Kansas Medical Center, Department of Microbiology, Immunology, and Molecular Genetics, Kansas City, KS; the American University of Beirut, Department of Internal Medicine, Beirut, Lebanon; Hopital Necker Universite Paris V, Centre National de la Recherche Scientifique Unite Mixte de Recherche 8603, Paris, France; and the National Cancer Institute, National Institutes of Health, Metabolism Branch, Center for Cancer Research, Bethesda, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Hermine","sequence":"additional","affiliation":[{"name":"From the University of Kansas Medical Center, Department of Microbiology, Immunology, and Molecular Genetics, Kansas City, KS; the American University of Beirut, Department of Internal Medicine, Beirut, Lebanon; Hopital Necker Universite Paris V, Centre National de la Recherche Scientifique Unite Mixte de Recherche 8603, Paris, France; and the National Cancer Institute, National Institutes of Health, Metabolism Branch, Center for Cancer Research, Bethesda, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Nicot","sequence":"additional","affiliation":[{"name":"From the University of Kansas Medical Center, Department of Microbiology, Immunology, and Molecular Genetics, Kansas City, KS; the American University of Beirut, Department of Internal Medicine, Beirut, Lebanon; Hopital Necker Universite Paris V, Centre National de la Recherche Scientifique Unite Mixte de Recherche 8603, Paris, France; and the National Cancer Institute, National Institutes of Health, Metabolism Branch, Center for Cancer Research, Bethesda, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111713153254300_REF1","doi-asserted-by":"crossref","unstructured":"Poiesz BJ, Ruscetti FW, Gazdar AF, et al. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci U S A. 1980;77: 7415-7419.","DOI":"10.1073\/pnas.77.12.7415"},{"key":"2019111713153254300_REF2","doi-asserted-by":"crossref","unstructured":"Yoshida M, Miyoshi I, Hinuma Y. Isolation and characterization of retrovirus from cell lines of human adult T-cell leukemia and its implication in the disease. Proc Natl Acad Sci U S A. 1982;79: 2031-2035.","DOI":"10.1073\/pnas.79.6.2031"},{"key":"2019111713153254300_REF3","doi-asserted-by":"crossref","unstructured":"Yoshida M. Multiple viral strategies of HTLV-1 for dysregulation of cell growth control. Annu Rev Immunol. 2001;19: 475-496.","DOI":"10.1146\/annurev.immunol.19.1.475"},{"key":"2019111713153254300_REF4","doi-asserted-by":"crossref","unstructured":"Bazarbachi A, Ghez D, Lepelletier Y, et al. New therapeutic approaches for adult T-cell leukaemia. Lancet Oncol. 2004;5: 664-672.","DOI":"10.1016\/S1470-2045(04)01608-0"},{"key":"2019111713153254300_REF5","doi-asserted-by":"crossref","unstructured":"Hermine O, Bouscary D, Gessain A, et al. Brief report: treatment of adult T-cell leukemia-lymphoma with zidovudine and interferon alfa. N Engl J Med. 1995;332: 1749-1751.","DOI":"10.1056\/NEJM199506293322604"},{"key":"2019111713153254300_REF6","doi-asserted-by":"crossref","unstructured":"White JD, Wharfe G, Stewart DM, et al. The combination of zidovudine and interferon alpha-2B in the treatment of adult T-cell leukemia\/lymphoma. Leuk Lymphoma. 2001;40: 287-294.","DOI":"10.3109\/10428190109057927"},{"key":"2019111713153254300_REF7","doi-asserted-by":"crossref","unstructured":"Gill PS, Harrington W Jr, Kaplan MH, et al. Treatment of adult T-cell leukemia-lymphoma with a combination of interferon alfa and zidovudine. N Engl J Med. 1995;332: 1744-1748.","DOI":"10.1056\/NEJM199506293322603"},{"key":"2019111713153254300_REF8","doi-asserted-by":"crossref","unstructured":"Langford A, Ruf B, Kunze R, Pohle HD, Reichart P. Regression of oral Kaposi's sarcoma in a case of AIDS on zidovudine (AZT). Br J Dermatol. 1989;120: 709-713.","DOI":"10.1111\/j.1365-2133.1989.tb01361.x"},{"key":"2019111713153254300_REF9","unstructured":"Lee RK, Cai JP, Deyev V, et al. Azidothymidine and interferon-alpha induce apoptosis in herpes-virus-associated lymphomas. Cancer Res. 1999;59: 5514-5520."},{"key":"2019111713153254300_REF10","unstructured":"Roychowdhury S, Peng R, Baiocchi RA, et al. Experimental treatment of Epstein-Barr virus-associated primary central nervous system lymphoma. Cancer Res. 2003;63: 965-971."},{"key":"2019111713153254300_REF11","doi-asserted-by":"crossref","unstructured":"Ghosh SK, Wood C, Boise LH, et al. Potentiation of TRAIL-induced apoptosis in primary effusion lymphoma through azidothymidine-mediated inhibition of NF-kappa B. Blood. 2003;101: 2321-2327.","DOI":"10.1182\/blood-2002-08-2525"},{"key":"2019111713153254300_REF12","doi-asserted-by":"crossref","unstructured":"Toomey NL, Deyev VV, Wood C, et al. Induction of a TRAIL-mediated suicide program by interferon alpha in primary effusion lymphoma. Oncogene. 2001;20: 7029-7040.","DOI":"10.1038\/sj.onc.1204895"},{"key":"2019111713153254300_REF13","doi-asserted-by":"crossref","unstructured":"Kurokawa M, Ghosh SK, Ramos JC, et al. Azidothymidine inhibits NF-kappaB and induces Epstein-Barr virus gene expression in Burkitt lymphoma. Blood. 2005;106: 235-240.","DOI":"10.1182\/blood-2004-09-3748"},{"key":"2019111713153254300_REF14","doi-asserted-by":"crossref","unstructured":"Hahn WC, Stewart SA, Brooks MW, et al. Inhibition of telomerase limits the growth of human cancer cells. Nat Med. 1999;5: 1164-1170.","DOI":"10.1038\/13495"},{"key":"2019111713153254300_REF15","doi-asserted-by":"crossref","unstructured":"Bryan TM, Englezou A, Dalla-Pozza L, Dunham MA, Reddel RR. Evidence for an alternative mechanism for maintaining telomere length in human tumors and tumor-derived cell lines. Nat Med. 1997;3: 1271-1274.","DOI":"10.1038\/nm1197-1271"},{"key":"2019111713153254300_REF16","doi-asserted-by":"crossref","unstructured":"Franzese O, Balestrieri E, Comandini A, et al. Telomerase activity of human peripheral blood mononuclear cells in the course of HTLV type 1 infection in vitro. AIDS Res Hum Retroviruses. 2002;18: 249-251.","DOI":"10.1089\/088922202753472810"},{"key":"2019111713153254300_REF17","doi-asserted-by":"crossref","unstructured":"Rufer N, Dragowska W, Thornbury G, Roosnek E, Lansdorp PM. Telomere length dynamics in human lymphocyte subpopulations measured by flow cytometry. Nat Biotechnol. 1998;16: 743-747.","DOI":"10.1038\/nbt0898-743"},{"key":"2019111713153254300_REF18","doi-asserted-by":"crossref","unstructured":"Kubuki Y, Suzuki M, Sasaki H, et al. Telomerase activity and telomere length as prognostic factors of adult T-cell leukemia. Leuk Lymphoma. 2005;46: 393-399.","DOI":"10.1080\/10428190400018349"},{"key":"2019111713153254300_REF19","doi-asserted-by":"crossref","unstructured":"Sinha-Datta U, Horikawa I, Michishita E, et al. Transcriptional activation of hTERT through the NF-kappaB pathway in HTLV-I\u2013transformed cells. Blood. 2004;104: 2523-2531.","DOI":"10.1182\/blood-2003-12-4251"},{"key":"2019111713153254300_REF20","doi-asserted-by":"crossref","unstructured":"Uchida N, Otsuka T, Arima F, et al. Correlation of telomerase activity with development and progression of adult T-cell leukemia. Leuk Res. 1999;23: 311-316.","DOI":"10.1016\/S0145-2126(98)00170-2"},{"key":"2019111713153254300_REF21","doi-asserted-by":"crossref","unstructured":"Bazarbachi A, Nasr R, El Sabban ME, et al. Evidence against a direct cytotoxic effect of alpha interferon and zidovudine in HTLV-I associated adult T cell leukemia\/lymphoma. Leukemia. 2000;14: 716-721.","DOI":"10.1038\/sj.leu.2401742"},{"key":"2019111713153254300_REF22","doi-asserted-by":"crossref","unstructured":"Strahl C, Blackburn EH. Effects of reverse transcriptase inhibitors on telomere length and telomerase activity in two immortalized human cell lines. Mol Cell Biol. 1996;16: 53-65.","DOI":"10.1128\/MCB.16.1.53"},{"key":"2019111713153254300_REF23","doi-asserted-by":"crossref","unstructured":"Counter CM, Avilion AA, LeFeuvre CE, et al. Telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity. EMBO J. 1992;11: 1921-1929.","DOI":"10.1002\/j.1460-2075.1992.tb05245.x"},{"key":"2019111713153254300_REF24","doi-asserted-by":"crossref","unstructured":"Zhang X, Mar V, Zhou W, Harrington L, Robinson MO. Telomere shortening and apoptosis in telomerase-inhibited human tumor cells. Genes Dev. 1999;13: 2388-2399.","DOI":"10.1101\/gad.13.18.2388"},{"key":"2019111713153254300_REF25","doi-asserted-by":"crossref","unstructured":"Nicot C, Mahieux R, Takemoto S, Franchini G. Bcl-X(L) is up-regulated by HTLV-I and HTLV-II in vitro and in ex vivo ATLL samples. Blood. 2000;96: 275-281.","DOI":"10.1182\/blood.V96.1.275"},{"key":"2019111713153254300_REF26","doi-asserted-by":"crossref","unstructured":"Mahieux R, Pise-Masison C, Gessain A, et al. Arsenic trioxide induces apoptosis in human T-cell leukemia virus type 1- and type 2-infected cells by a caspase-3\u2013dependent mechanism involving Bcl-2 cleavage. Blood. 2001;98: 3762-3769.","DOI":"10.1182\/blood.V98.13.3762"},{"key":"2019111713153254300_REF27","unstructured":"El Sabban ME, Nasr R, Dbaibo G, et al. Arsenic-interferon-alpha\u2013triggered apoptosis in HTLV-I transformed cells is associated with tax down-regulation and reversal of NF-kappa B activation. Blood. 2000;96: 2849-2855."},{"key":"2019111713153254300_REF28","doi-asserted-by":"crossref","unstructured":"Dimri GP, Itahana K, Acosta M, Campisi J. Regulation of a senescence checkpoint response by the E2F1 transcription factor and p14(ARF) tumor suppressor. Mol Cell Biol. 2000;20: 273-285.","DOI":"10.1128\/MCB.20.1.273-285.2000"},{"key":"2019111713153254300_REF29","doi-asserted-by":"crossref","unstructured":"Momand J, Zambetti GP, Olson DC, George D, Levine AJ. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell. 1992;69: 1237-1245.","DOI":"10.1016\/0092-8674(92)90644-R"},{"key":"2019111713153254300_REF30","doi-asserted-by":"crossref","unstructured":"Pan Y, Chen J. MDM2 promotes ubiquitination and degradation of MDMX. Mol Cell Biol. 2003;23: 5113-5121.","DOI":"10.1128\/MCB.23.15.5113-5121.2003"},{"key":"2019111713153254300_REF31","unstructured":"Reid RL, Lindholm PF, Mireskandari A, Dittmer J, Brady JN. Stabilization of wild-type p53 in human T-lymphocytes transformed by HTLV-I. Oncogene. 1993;8: 3029-3036."},{"key":"2019111713153254300_REF32","doi-asserted-by":"crossref","unstructured":"Takemoto S, Trovato R, Cereseto A, et al. p53 stabilization and functional impairment in the absence of genetic mutation or the alteration of the p14(ARF)-MDM2 loop in ex vivo and cultured adult T-cell leukemia\/lymphoma cells. Blood. 2000;95: 3939-3944.","DOI":"10.1182\/blood.V95.12.3939"},{"key":"2019111713153254300_REF33","doi-asserted-by":"crossref","unstructured":"Cereseto A, Washington PR, Rivadeneira E, Franchini G. Limiting amounts of p27Kip1 correlates with constitutive activation of cyclin E-CDK2 complex in HTLV-I\u2013transformed T-cells. Oncogene. 1999;18: 2441-2450.","DOI":"10.1038\/sj.onc.1202567"},{"key":"2019111713153254300_REF34","unstructured":"Wagner CR, Ballato G, Akanni AO, et al. Potent growth inhibitory activity of zidovudine on cultured human breast cancer cells and rat mammary tumors. Cancer Res. 1997;57: 2341-2345."},{"key":"2019111713153254300_REF35","doi-asserted-by":"crossref","unstructured":"Hermine O, Allard I, Levy V, et al. A prospective phase II clinical trial with the use of zidovudine and interferon-alpha in the acute and lymphoma forms of adult T-cell leukemia\/lymphoma. Hematol J. 2002;3: 276-282.","DOI":"10.1038\/sj.thj.6200195"},{"key":"2019111713153254300_REF36","doi-asserted-by":"crossref","unstructured":"Sakashita A, Hattori T, Miller CW, et al. Mutations of the p53 gene in adult T-cell leukemia. Blood. 1992;79: 477-480.","DOI":"10.1182\/blood.V79.2.477.477"},{"key":"2019111713153254300_REF37","doi-asserted-by":"crossref","unstructured":"Slijepcevic P. Telomere length measurement by Q-FISH. Methods Cell Sci. 2001;23: 17-22.","DOI":"10.1023\/A:1013177128297"},{"key":"2019111713153254300_REF38","doi-asserted-by":"crossref","unstructured":"Inoue J, Seiki M, Taniguchi T, Tsuru S, Yoshida M. Induction of interleukin 2 receptor gene expression by p40x encoded by human T-cell leukemia virus type 1. EMBO J. 1986;5: 2883-2888.","DOI":"10.1002\/j.1460-2075.1986.tb04583.x"},{"key":"2019111713153254300_REF39","doi-asserted-by":"crossref","unstructured":"Hatta Y, Hirama T, Miller CW, et al. Homozygous deletions of the p15 (MTS2) and p16 (CDKN2\/MTS1) genes in adult T-cell leukemia. Blood. 1995;85: 2699-2704.","DOI":"10.1182\/blood.V85.10.2699.bloodjournal85102699"},{"key":"2019111713153254300_REF40","unstructured":"Nosaka K, Maeda M, Tamiya S, et al. Increasing methylation of the CDKN2A gene is associated with the progression of adult T-cell leukemia. Cancer Res. 2000;60: 1043-1048."},{"key":"2019111713153254300_REF41","doi-asserted-by":"crossref","unstructured":"Uchida T, Kinoshita T, Murate T, Saito H, Hotta T. CDKN2 (MTS1\/p16INK4A) gene alterations in adult T-cell leukemia\/lymphoma. Leuk Lymphoma. 1998;29: 27-35.","DOI":"10.3109\/10428199809058379"},{"key":"2019111713153254300_REF42","doi-asserted-by":"crossref","unstructured":"Trovato R, Cereseto A, Takemoto S, et al. Deletion of the p16INK4A gene in ex vivo acute adult T cell lymphoma\/leukemia cells and methylation of the p16INK4A promoter in HTLV type I\u2013infected T cell lines. AIDS Res Hum Retroviruses. 2000;16: 709-713.","DOI":"10.1089\/088922200308701"},{"key":"2019111713153254300_REF43","doi-asserted-by":"crossref","unstructured":"Llanos S, Clark PA, Rowe J, Peters G. Stabilization of p53 by p14ARF without relocation of MDM2 to the nucleolus. Nat Cell Biol. 2001;3: 445-452.","DOI":"10.1038\/35074506"},{"key":"2019111713153254300_REF44","doi-asserted-by":"crossref","unstructured":"Miyazato A, Sheleg S, Iha H, Li Y, Jeang KT. Evidence for NF-kappaB- and CBP-independent repression of p53\u2032s transcriptional activity by human T-cell leukemia virus type 1 Tax in mouse embryo and primary human fibroblasts. J Virol. 2005;79: 9346-9350.","DOI":"10.1128\/JVI.79.14.9346-9350.2005"},{"key":"2019111713153254300_REF45","doi-asserted-by":"crossref","unstructured":"Jeong SJ, Radonovich M, Brady JN, Pise-Masison CA. HTLV-I Tax induces a novel interaction between p65\/RelA and p53 that results in inhibition of p53 transcriptional activity. Blood. 2004;104: 1490-1497.","DOI":"10.1182\/blood-2003-12-4174"},{"key":"2019111713153254300_REF46","doi-asserted-by":"crossref","unstructured":"Mahieux R, Pise-Masison CA, Nicot C, et al. Inactivation of p53 by HTLV type 1 and HTLV type 2 Tax trans-activators. AIDS Res Hum Retroviruses. 2000;16: 1677-1681.","DOI":"10.1089\/08892220050193137"},{"key":"2019111713153254300_REF47","doi-asserted-by":"crossref","unstructured":"Pise-Masison CA, Mahieux R, Radonovich M, Jiang H, Brady JN. Human T-lymphotropic virus type I Tax protein utilizes distinct pathways for p53 inhibition that are cell type-dependent. J Biol Chem. 2001;276: 200-205.","DOI":"10.1074\/jbc.M005601200"},{"key":"2019111713153254300_REF48","doi-asserted-by":"crossref","unstructured":"Mulloy JC, Kislyakova T, Cereseto A, et al. Human T-cell lymphotropic\/leukemia virus type 1 Tax abrogates p53-induced cell cycle arrest and apoptosis through its CREB\/ATF functional domain. J Virol. 1998;72: 8852-8860.","DOI":"10.1128\/JVI.72.11.8852-8860.1998"},{"key":"2019111713153254300_REF49","doi-asserted-by":"crossref","unstructured":"Pise-Masison CA, Radonovich M, Sakaguchi K, Appella E, Brady JN. Phosphorylation of p53: a novel pathway for p53 inactivation in human T-cell lymphotropic virus type 1\u2013transformed cells. J Virol. 1998;72: 6348-6355.","DOI":"10.1128\/JVI.72.8.6348-6355.1998"},{"key":"2019111713153254300_REF50","doi-asserted-by":"crossref","unstructured":"Pise-Masison CA, Choi KS, Radonovich M, et al. Inhibition of p53 transactivation function by the human T-cell lymphotropic virus type 1 Tax protein. J Virol. 1998;72: 1165-1170.","DOI":"10.1128\/JVI.72.2.1165-1170.1998"},{"key":"2019111713153254300_REF51","doi-asserted-by":"crossref","unstructured":"Arnulf B, Villemain A, Nicot C, et al. Human T-cell lymphotropic virus oncoprotein Tax represses TGF-beta 1 signaling in human T cells via c-Jun activation: a potential mechanism of HTLV-I leukemogenesis. Blood. 2002;100: 4129-4138.","DOI":"10.1182\/blood-2001-12-0372"},{"key":"2019111713153254300_REF52","doi-asserted-by":"crossref","unstructured":"Lee DK, Kim BC, Brady JN, Jeang KT, Kim SJ. Human T-cell lymphotropic virus type 1 tax inhibits transforming growth factor-beta signaling by blocking the association of Smad proteins with Smad-binding element. J Biol Chem. 2002;277: 33766-33775.","DOI":"10.1074\/jbc.M200150200"},{"key":"2019111713153254300_REF53","doi-asserted-by":"crossref","unstructured":"Mori N, Morishita M, Tsukazaki T, et al. Human T-cell leukemia virus type I oncoprotein Tax represses Smad-dependent transforming growth factor beta signaling through interaction with CREB-binding protein\/p300. Blood. 2001;97: 2137-2144.","DOI":"10.1182\/blood.V97.7.2137"},{"key":"2019111713153254300_REF54","doi-asserted-by":"crossref","unstructured":"Kadakia M, Brown TL, McGorry MM, Berberich SJ. MdmX inhibits Smad transactivation. Oncogene. 2002;21: 8776-8785.","DOI":"10.1038\/sj.onc.1205993"},{"key":"2019111713153254300_REF55","unstructured":"Yam CH, Siu WY, Arooz T, et al. MDM2 and MDMX inhibit the transcriptional activity of ectopically expressed SMAD proteins. Cancer Res. 1999;59: 5075-5078."},{"key":"2019111713153254300_REF56","doi-asserted-by":"crossref","unstructured":"Mone A, Puhalla S, Whitman S, et al. Durable hematological complete response and suppression of HTLV-1 viral load following alemtuzumab in AZT\/IFN{alpha}-refractory adult T-cell leukemia. Blood. 2005;106: 3380-3382.","DOI":"10.1182\/blood-2005-01-0335"},{"key":"2019111713153254300_REF57","unstructured":"Zhang Z, Zhang M, Goldman CK, Ravetch JV, Waldmann TA. Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD52 monoclonal antibody, Campath-1H. Cancer Res. 2003;63: 6453-6457."},{"key":"2019111713153254300_REF58","doi-asserted-by":"crossref","unstructured":"Lozanski G, Heerema NA, Flinn IW, et al. Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood. 2004;103: 3278-3281.","DOI":"10.1182\/blood-2003-10-3729"},{"key":"2019111713153254300_REF59","doi-asserted-by":"crossref","unstructured":"Stilgenbauer S, Dohner H. Campath-1H\u2013induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy. N Engl J Med. 2002;347: 452-453.","DOI":"10.1056\/NEJM200208083470619"},{"key":"2019111713153254300_REF60","unstructured":"Obama K, Tara M, Sao H, et al. Allogenic bone marrow transplantation as a treatment for adult T-cell leukemia. Int J Hematol. 1999;69: 203-205."},{"key":"2019111713153254300_REF61","doi-asserted-by":"crossref","unstructured":"Waldmann TA, White JD, Carrasquillo JA, et al. Radioimmunotherapy of interleukin-2R alpha-expressing adult T-cell leukemia with Yttrium-90\u2013labeled anti-Tac. Blood. 1995;86: 4063-4075.","DOI":"10.1182\/blood.V86.11.4063.bloodjournal86114063"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/108\/3\/1021\/1281719\/zh801506001021.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/108\/3\/1021\/1281719\/zh801506001021.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,13]],"date-time":"2020-04-13T11:51:00Z","timestamp":1586778660000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/108\/3\/1021\/22336\/Persistent-inhibition-of-telomerase-reprograms"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,8,1]]},"references-count":61,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2006,8,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2006-01-0067","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,8,1]]}}}